NYSE$MTNB
Matinas BioPharma Holdings Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Matinas BioPharma reported financial results for the fourth quarter and full year ended December 31, 2021.
Matinas BioPharma reported a net loss attributable to common shareholders of $6.7 million, or a net loss of $0.03 per share for the fourth quarter of 2021. The company's cash, cash equivalents and marketable securities were approximately $49.6 million at the end of the year, which is expected to fund planned operations through 2023.
- Fifteen patients enrolled to date in Cohort 4 of EnACT with topline interim data expected in Q3 2022.
- Potential pathway to NDA submission for MAT2203 with confirmatory data to come from Cohort 5 of EnACT Trial.
- Second in vivo study of Oral LNC-remdesivir to commence in March 2022.
- Moving aggressively into Nucleic Acids with Internal Discovery Programs Initiated with mRNA, DNA and Antisense Oligonucleotides (ASOs).
Headline financials
Revenue & EPS history
Matinas BioPharma · Revenue · Quarterly
$0
Forward guidance
Based on current projections, the Company believes that cash on hand is sufficient to fund planned operations through 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
-2.1%
Avg return
Earnings day
-2.9%
Avg return
5 days after
-1.9%
Avg return
30 days after
37%
14 / 38 earnings
Positive
+43.0%
Q2 2025
Best reaction
-41.3%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | +2.6% | +4.3% | -32.2% | |
| Q2 2025 | +43.0% | +5.5% | +10.9% | |
| Q2 2024 | -1.3% | +9.0% | +17.3% | |
| Q1 2025 | +6.3% | +2.5% | +15.0% | |
| Q4 2025 | -6.0% | -7.5% | +21.2% | |
| Q3 2024 | -15.0% | -18.1% | -23.9% | |
| Q1 2024 | -1.1% | -1.1% | -10.7% | |
| Q4 2023 | -5.2% | +29.4% | -37.4% | |
| Q3 2023 | -24.3% | -31.9% | -21.9% | |
| Q2 2023 | -41.3% | -50.0% | -50.9% | |
| Q1 2023 | -12.5% | -15.5% | -26.0% | |
| Q4 2022 | +2.1% | -11.1% | -2.2% | |
| Q3 2022 | -3.3% | -5.0% | -15.2% | |
| Q2 2022 | -4.7% | -8.4% | -12.9% | |
| Q1 2022 | +6.7% | +6.5% | +32.0% | |
| Q4 2021 | +12.9% | +6.9% | +40.0% | |
| Q3 2021 | -6.8% | -2.8% | +3.7% | |
| Q2 2021 | -2.5% | -5.7% | +2.7% | |
| Q1 2021 | +2.6% | -3.8% | +7.1% | |
| Q4 2020 | -2.7% | -1.8% | -98.3% | |
| Q3 2020 | -2.6% | -3.6% | +29.0% | |
| Q2 2020 | -3.8% | -7.2% | -22.0% | |
| Q1 2020 | +8.9% | +11.7% | +29.7% | |
| Q4 2019 | -14.6% | -34.0% | -49.1% | |
| Q3 2019 | -4.8% | +31.2% | +96.8% | |
| Q2 2019 | +6.2% | +6.7% | +2.1% | |
| Q1 2019 | +1.8% | +10.0% | -7.8% | |
| Q4 2018 | -0.9% | -1.8% | -7.2% | |
| Q3 2018 | -25.2% | -29.8% | -28.8% | |
| Q2 2018 | -1.4% | +5.0% | +26.1% | |
| Q1 2018 | -1.0% | +0.6% | +8.6% | |
| Q4 2017 | -5.5% | -12.8% | -38.8% | |
| Q3 2017 | +2.6% | +4.4% | +24.6% | |
| Q2 2017 | +14.4% | +5.6% | +9.6% | |
| Q1 2017 | +2.9% | +7.6% | -7.3% | |
| Q3 2016 | -6.3% | -4.0% | -20.0% | |
| Q2 2016 | +3.2% | +1.5% | +64.7% | |
| Q1 2016 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q3 2014 | -3.3% | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro